Sanofi is celebrating a pair of regulatory successes for drugs that will be the first treatments to be approved for two rare diseases, acid sphingomyelinase deficiency (ASMD) and eosinophilic esophagitis (EoE).
First up is another approval in the US for the mega-blockbuster Dupixent (dupilumab) which has just received the green light from the Food and Drug Administration for EoE, a chronic disease driven by type 2 inflammation that damages the esophagus and prevents it from working properly, making swallowing a painful and worrisome choking experience
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?